# Sinotau Pharmaceutical Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sinotau-pharmaceutical-group

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.sinotau.com
- Total disclosed funding: $292M
- Latest round: Series E (Jul 3, 2023)
- Investors on record: 30

## About

Established in 2005 and based in Beijing, China, Sinotau Pharmaceutical Group operates as a biopharmaceutical company that provides targeted therapy and precision diagnostic radiopharmaceuticals. The company has molecular imaging bases in Jiangsu, Guangdong and Sichuan. It cooperates with over 300 hospitals, such as Biogen, Merck and abbvie,  and the academic outreach team has more than 100 members. In 2017, the company established Jiangsu and Guangdong Branch. In December 2021, it obtained a radiation safety license and established Shanghai R&D Center. In July 2023, it raised over CNY 1.1 billion in series E funding from Beijing GAGE Capital Management Company Ltd. and CCT Fund Management, etc.

The company's product pipelines are divided into two series, which include the radiopharmaceuticals field and the biopharmaceuticals field. The radiopharmaceuticals field focuses on the development of antibody biologics, and can treat patients with tumors, neurodegenerative diseases and autoimmune diseases. The species of the biopharmaceuticals field involved in 18F, 13C and 14C series nuclides. In addition, the company engages in academic promotion through various ways, including public numbers (Hexing Liaowang), literature publication, journal submission, expert collaboration, academic seminar salon, summit forum and clinical trial data interpretation.

## Funding rounds

- Series E, Jul 3, 2023, $152M — Guangdong Technology Financial Group, CITIC Securities, Lotus Lake Capital, Wuxi Huading Venture Capital, General Technology Venture Capital, Wuhan Leaddo Measuring & Control Co., Ltd, Goldstone Capital, CCT Fund Management, SDIC Venture Capital, China Life Capital, GF Qianhe, Ennovation Ventures, SDIC Chuangyi, Jiangxi Jemincare Group Co., Ltd., GAGE Capital, Shanghai Zhizhong Private Equity Fund Management, Chongqing Qingshi Zhenhe Equity Investment Fund Management Co., Ltd., Xinshang Investment, Chengming Capital, Zhongshan Venture Capital
- Series D, Oct 21, 2021, $50M — Centurium Cap, Deyi Capital, China Life Capital, Panya Studios Pte. Ltd., Tianjin Yingya Equity Investment Fund Management
- Series D, Feb 23, 2021, $49M — China International Capital Corporation, Lotus Lake Capital, Everest VC, Zhuhai Longmen Capital Management, Tianjin Yingya Equity Investment Fund Management, Deyi Capital
- Series C, Sep 4, 2020, $41M — CASH Capital, Lotus Lake Capital, Shanghai Jianyi Private Equity Fund Management, Wuming Venture

## Investors

- CASH Capital (https://capitalatlas.ai/funds/cash-capital) — Series C
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series C, Series D, Series E
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series C
- Wuming Venture (https://capitalatlas.ai/funds/wuming-venture) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series D
- Everest VC (https://capitalatlas.ai/funds/everest-vc) — Series D
- Zhuhai Longmen Capital Management (https://capitalatlas.ai/funds/zhuhai-longmen-capital-management) — Series D
- Tianjin Yingya Equity Investment Fund Management — Series D
- Deyi Capital (https://capitalatlas.ai/funds/deyi-capital) — Series D
- Centurium Cap — Series D
- China Life Capital — Series D, Series E
- Panya Studios Pte. Ltd. — Series D
- Guangdong Technology Financial Group (https://capitalatlas.ai/funds/guangdong-technology-financial-group) — Series E
- CITIC Securities — Series E
- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series E
- General Technology Venture Capital (https://capitalatlas.ai/funds/general-technology-venture-capital) — Series E
- Wuhan Leaddo Measuring & Control Co., Ltd — Series E
- Goldstone Capital — Series E
- CCT Fund Management — Series E
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series E
- GF Qianhe — Series E
- Ennovation Ventures (https://capitalatlas.ai/funds/ennovation-ventures) — Series E
- SDIC Chuangyi (https://capitalatlas.ai/funds/sdic-chuangyi) — Series E
- Jiangxi Jemincare Group Co., Ltd. — Series E
- GAGE Capital (https://capitalatlas.ai/funds/gage-capital) — Series E
- Shanghai Zhizhong Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-zhizhong-private-equity-fund-management) — Series E
- Chongqing Qingshi Zhenhe Equity Investment Fund Management Co., Ltd. — Series E
- Xinshang Investment (https://capitalatlas.ai/funds/xinshang-investment) — Series E
- Chengming Capital — Series E
- Zhongshan Venture Capital (https://capitalatlas.ai/funds/zhongshan-venture-capital) — Series E